CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...